Clinical Trial Update: A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Sustained HBsAg Loss) (B) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating a combination of an anti-PD-1 antibody and Peg-IFNα for chronic hepatitis B with the goal of sustained HBsAg loss; the st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Anti-PD-1 antibody
• PEG-IFNα (pegylated interferon alfa)

Snippet

Sponsor: The Second Affiliated Hospital of Chongqing Medical University | Conditions: Chronic Hepatitis b, Anti-PD-1 Antibody | Phase 2 | Status: RECRUITING